
# Title 42 - Public Health
## Chapter IV - Centers for Medicare & Medicaid Services, Department of Health and Human Services
### Subchapter B - Medicare Program
#### PART 413 - PRINCIPLES OF REASONABLE COST REIMBURSEMENT; PAYMENT FOR END-STAGE RENAL DISEASE SERVICES; PROSPECTIVELY DETERMINED PAYMENT RATES FOR SKILLED NURSING FACILITIES; PAYMENT FOR ACUTE KIDNEY INJURY DIALYSIS
##### Subpart H - Payment for End-Stage Renal Disease (ESRD) Services
###### ยง 413.234 Drug designation process.
####### Type 5 NDA

(i) Ais for a product, other than a new dosage form, that differs from a product already approved or marketed in the U.S. because of one of the following:

(A) The product involves changes in inactive ingredients that require either bioequivalence studies or clinical studies for approval and is submitted as an original NDA rather than as a supplement by the applicant of the approved product;

(B) The product is a duplicate of a drug product by another applicant (same active ingredient, same dosage form, same or different indication, or same combination), and
